🔗 Visit the ClinicalTrials.gov page for NCT00523848
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. | Br J Haematol | 2011 | 0.79 |